- Trial phase
- Approved
- Time to market
- Already on the market since 2005.
- Why 3/10
- ProQuad is an already-approved, marketed vaccine with no pending PDUFA date, Advisory Committee meeting, or pivotal readout scheduled in the next 12 months. It is a mature product within Merck's massive $67 billion portfolio, and the combined MMRV franchise (ProQuad + M-M-R II + Varivax) generates only about $538 million annually, less than 1% of total revenue. No binary catalyst exists to drive a meaningful share-price move.
ProQuad has no scheduled PDUFA date, AdComm, or pivotal readout in the next 12 months. As a mature, approved vaccine, its commercial trajectory will be driven by routine pediatric immunization rates and competition from GSK's Priorix, not by any binary catalyst. For MRK investors, the drug is a negligible revenue contributor within a $67 billion portfolio dominated by Keytruda and Gardasil.
Price Chart
Executive Summary
ProQuad is Merck's combination vaccine (MMRV) that protects children aged 12 months to 12 years against measles, mumps, rubella, and varicella (chickenpox). It was first FDA-approved in September 2005 and is a well-established, commercially marketed product. Recent label updates include FDA approval of an intramuscular route of administration (March 2023) and a concomitant-use supplement (November 2024). ProQuad is grouped with Merck's other pediatric vaccines (M-M-R II and Varivax) for reporting; that combined franchise generated roughly $538 million in 2026, a tiny fraction of Merck's ~$67 billion total revenue. There are no pending regulatory decisions or pivotal readouts for this drug, making it a non-event for MRK shareholders.
How It Works
ProQuad is a combination vaccine that contains weakened live forms of the measles, mumps, rubella, and varicella (chickenpox) viruses. When injected, it stimulates the child's immune system to produce antibodies against all four diseases without causing the illnesses themselves, providing long-term protection.
Trial Status
ProQuad was initially FDA-approved in September 2005. The FDA approved an intramuscular (IM) route of administration in March 2023, and a supplemental BLA for concomitant administration data was approved in November 2024. The vaccine is commercially marketed in the U.S. and globally.
The Two-Sided Case
Upcoming Catalysts
- No hard, dated catalysts (PDUFA, AdComm, or pivotal readout) are scheduled for ProQuad in the next 12 months. The drug is a mature, approved product with no pending regulatory events.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report